Trials / Completed
CompletedNCT05089019
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
An Open-Label, Randomized Study to Evaluate the Bioequivalence of Selpercatinib Formulations
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- Loxo Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 56 days including the 28 days of screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selpercatinib | Administered orally |
Timeline
- Start date
- 2021-10-29
- Primary completion
- 2022-07-19
- Completion
- 2022-07-19
- First posted
- 2021-10-22
- Last updated
- 2025-03-17
- Results posted
- 2025-03-17
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05089019. Inclusion in this directory is not an endorsement.